Galapagos NV

Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

03 Oct 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

27 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos receives transparency notification from FMR LLC

29 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos to present at upcoming investor conferences

24 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos receives transparency notification from FMR LLC

18 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

First key steps in pipeline rebuild and strong commercial progress in H1 2022

04 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies

21 Jun 2022 16:03:08 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

20 Jun 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos receives transparency notification from FMR LLC

01 Jun 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress

25 May 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos creates new subscription right plans

06 May 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos demonstrates regulatory and commercial progress in Q1 2022

05 May 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board

26 Apr 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings

24 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

18 Mar 2022 17:01:00 By Nasdaq GlobeNewswire

Galapagos 2021 results set stage for future growth

24 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos receives transparency notification from EcoR1 Capital

03 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress

02 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos creates new subscription right plan

26 Jan 2022 16:40:00 By Nasdaq GlobeNewswire

Galapagos appoints Paul Stoffels as Chief Executive Officer

26 Jan 2022 16:01:00 By Nasdaq GlobeNewswire